Report cover image

Myocardial Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Nov 30, 2022
Length 54 Pages
SKU # GMD17776495

Description

Myocardial Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Drugs In Development, 2022, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

54 Pages
Introduction
Global Markets Direct Report Coverage
Myocardial Fibrosis – Overview
Myocardial Fibrosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Fibrosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Fibrosis – Companies Involved in Therapeutics Development
Evotec SE
Galectin Therapeutics Inc
Guangdong Maijinjia Biotechnologies Co Ltd
Invivosciences Inc
Lead Discovery Center GmbH
MandalMed Inc
NovoMedix LLC
Palatin Technologies Inc
Pharmaxis Ltd
Puretech Health Plc
TRACON Pharmaceuticals Inc
Vectus Biosystems Ltd
Myocardial Fibrosis – Drug Profiles
belapectin – Drug Profile
deupirfenidone – Drug Profile
Drugs for Tissue Fibrosis – Drug Profile
Fibrosis in Heart Muscle – Drug Profile
GMCT-01 – Drug Profile
GYY-4137 – Drug Profile
IVS-201 – Drug Profile
IVS-202 – Drug Profile
Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases – Drug Profile
NM-922 – Drug Profile
PL-5028 – Drug Profile
PN1-Ab – Drug Profile
PXS-5153A – Drug Profile
PXS-5382A – Drug Profile
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology – Drug Profile
RHO GEF – Drug Profile
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis – Drug Profile
TPI-2049 – Drug Profile
TRC-205 – Drug Profile
VB-0004 – Drug Profile
Myocardial Fibrosis – Dormant Projects
Myocardial Fibrosis – Discontinued Products
Myocardial Fibrosis – Product Development Milestones
Featured News & Press Releases
Oct 08, 2019: Publication that demonstrates reversal of established fibrosis in a preclinical model of cardiac fibrosis by VIP
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Myocardial Fibrosis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Universities/Institutes, 2022
Table 6: Number of Products by Stage and Target, 2022
Table 7: Number of Products by Stage and Mechanism of Action, 2022
Table 8: Number of Products by Stage and Route of Administration, 2022
Table 9: Number of Products by Stage and Molecule Type, 2022
Table 10: Myocardial Fibrosis – Pipeline by Evotec SE, 2022
Table 11: Myocardial Fibrosis – Pipeline by Galectin Therapeutics Inc, 2022
Table 12: Myocardial Fibrosis – Pipeline by Guangdong Maijinjia Biotechnologies Co Ltd, 2022
Table 13: Myocardial Fibrosis – Pipeline by Invivosciences Inc, 2022
Table 14: Myocardial Fibrosis – Pipeline by Lead Discovery Center GmbH, 2022
Table 15: Myocardial Fibrosis – Pipeline by MandalMed Inc, 2022
Table 16: Myocardial Fibrosis – Pipeline by NovoMedix LLC, 2022
Table 17: Myocardial Fibrosis – Pipeline by Palatin Technologies Inc, 2022
Table 18: Myocardial Fibrosis – Pipeline by Pharmaxis Ltd, 2022
Table 19: Myocardial Fibrosis – Pipeline by Puretech Health Plc, 2022
Table 20: Myocardial Fibrosis – Pipeline by TRACON Pharmaceuticals Inc, 2022
Table 21: Myocardial Fibrosis – Pipeline by Vectus Biosystems Ltd, 2022
Table 22: Myocardial Fibrosis – Dormant Projects, 2022
Table 23: Myocardial Fibrosis – Dormant Projects, 2022 (Contd..1)
Table 24: Myocardial Fibrosis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Myocardial Fibrosis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us